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Antonio F. Santidrian1, Duong Nguyen1, Dobrin Draganov1, Mehmet O. Killinc1, Anna Vyalkova5,
Santosh Kesari6, Edward McClay7, Gabriel Carabulea8, Francesco M. Marincola9, Lisa H. Butterfield10
and Aladar A. Szalay1,2,5

Abstract
Background: ACAM2000, a thymidine kinase (TK)-positive strain of vaccinia virus, is the current smallpox vaccine in the
US. Preclinical testing demonstrated potent oncolytic activity of ACAM2000 against several tumor types. This Phase I clinical trial of ACAM2000 delivered by autologous adipose stromal vascular fraction (SVF) cells was conducted to determine
the safety and feasibility of such a treatment in patients with advanced solid tumors or acute myeloid leukemia (AML).
Methods: Twenty-four patients with solid tumors and two patients with AML participated in this open-label, nonrandomized dose-escalation trial. All patients were treated with SVF derived from autologous fat and incubated for
15 min to 1 h with ACAM2000 before application. Six patients received systemic intravenous application only, one
patient received intra-tumoral application only, 15 patients received combination intravenous with intra-tumoral
deployment, 3 patients received intravenous and intra-peritoneal injection and 1 patient received intravenous, intratumoral and intra-peritoneal injections. Safety at each dose level of ACAM2000 (1.4 × 106 plaque-forming units (PFU)
to 1.8 × 107 PFU) was evaluated. Blood samples for PK assessments, flow cytometry and cytokine analysis were collected at baseline and 1 min, 1 h, 1 day, 1 week, 1 month, 3 months and 6 months following treatment.
Results: No serious toxicities (> grade 2) were reported. Seven patients reported an adverse event (AE) in this study:
self-limiting skin rashes, lasting 7 to 18 days—an expected adverse reaction to ACAM2000. No AEs leading to study
discontinuation were reported. Viral DNA was detected in all patients’ blood samples immediately following treatment. Interestingly, in 8 patients viral DNA disappeared 1 day and re-appeared 1 week post treatment, suggesting
active viral replication at tumor sites, and correlating with longer survival of these patients. No major increase in
cytokine levels or correlation between cytokine levels and skin rashes was noted. We were able to assess some initial
efficacy signals, especially when the ACAM2000/SVF treatment was combined with checkpoint inhibition.
Conclusions: Treatment with ACAM2000/SVF in patients with advanced solid tumors or AML is safe and well tolerated, and several patients had signals of an anticancer effect. These promising initial clinical results merit further
investigation of therapeutic utility.
Trial registration Retrospectively registered (ISRCTN#10201650) on October 22, 2018.
Keywords: Clinical trial, Oncolytic vaccinia virus, Stromal vascular fraction, Immunotherapy of cancer
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Background
Due to the vast knowledge expansion in tumor immunology in recent years, immunotherapy is quickly becoming
a major cancer treatment modality [1]. At the same time,
several major obstacles to the successful cancer immunotherapy are emerging. Immune suppressive microenvironment at tumor sites is a significant hindrance, leading
to limited responsiveness to modern immunotherapeutic agents in many tumor types [2]. These “cold” tumors
are lacking infiltration of Th1-polarized immune effector
cells and this characteristic is generally associated with
poor clinical prognosis [3, 4, 5] and diminished likelihood
of responding to immunotherapy such as checkpoint
inhibitor therapy [6].
A promising strategy to activate the immune system
at the tumor sites is the use of oncolytic viruses. Many
recent studies are confirming the ability of oncolytic
viruses to enhance immune cell infiltration, thus converting “cold” tumors into “hot” tumors, potentially leading
to a better responsiveness to the current combination
immunotherapy approaches [7–9].
Currently, a number of oncolytic viruses including vaccinia virus, herpes simplex virus-1, adenovirus, ECHO7, seneca valley virus, reovirus and other viruses are at
various stages of clinical development [10]. The ideal
oncolytic virus would be very safe to treat even severely
immuno-suppressed cancer patients, would have potent
anti-tumor properties against multiple tumor types, and
would be able to attack and kill all tumor cells at distant
metastatic sites. It would be easily manufactured and
stored for widespread use. Further, the need for genetic
manipulation of the virus would be minimal. None of the
viruses currently under investigation has the ability to
fulfill this ideal viral phenotype. However, the oncolytic
vaccinia virus may satisfy many of the above criteria.
Vaccinia virus (VV) is a large and complex particle containing a single linear double-stranded DNA genome of
approximately 190 kb, encoding approximately 150–200
proteins [11]. This virus has many characteristics desirable in an oncolytic virus for clinical applications: (1)
short, well-characterized life cycle, spreading very rapidly
from cell-to-cell, (2) highly cytolytic for a broad range of
tumor cell types, (3) a large insertion capacity (> 25 kb)
for the expression of exogenous genes if required, (4)
high genetic stability, (5) amenable to large scale production of high levels of infectious virus; (6) does not cause
any known diseases in humans, (7) remains in the cytoplasm and does not enter the host cell nucleus during the
entire life cycle, and thus does not integrate into the host
genome, (8) used extensively as smallpox vaccine in millions of people with well documented safety profile [12],
(9) drugs (e.g. vaccinia immunoglobulin, cidofovir, etc.)
are available to effectively treat any potential vaccinia
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infections, and (10) has previously been safely administered to patients with advanced cancer [13] [14].
Majority of known VV strains were used as vaccines
in the World Health Organization Smallpox Eradication
Program (1966–1980). In the US, the main VV strain
used was Dryvax—used as smallpox vaccine until 2008
when it was substituted by ACAM2000 (Acambis, Inc.™),
a single plaque-purified vaccinia virus derivative of Dryvax [15, 12], selected based on its reduced virulence [16,
17].
ACAM2000 genome carries key genomic alterations that explain its reduced virulence [18]. Two main
disrupted factors are immunomodulatory: (i) a tumor
necrosis factor receptor, and (ii) the interferon α/β binding protein [18]. Moreover, ACAM2000 genome presents
other genomic alterations that might contribute to its
naturally occurring reduced virulence, namely a truncation of ankyrin-repeat ortholog of a VARV (Variola)-and
CPXV (cowpox)-like protein and a short form of the thymidylate kinase gene [18].
To reduce the risk of therapeutic use of vaccinia virus,
highly virulent vaccinia virus strains like Western Reserve
have been genetically-engineered to attenuate the virus
and to improve safety [19–21]. Elimination of TK gene
from the virulent Western Reserve strain decreased significantly the lethality of mice injected intra-cranially
with the virus [21]. Therefore, the TK gene from vaccinia
virus genome became the primary target to attenuate
highly virulent viruses or viruses with unknown virulence. In contrast, the ACAM2000 derivation exemplifies an alternative strategy to generate a safer vaccinia
virus: selection of a naturally occurring clone with a significantly reduced virulence and improved safety profile.
Therefore, the TK-positive ACAM2000 possesses both
strong anti-tumor activities associated with unattenuated
viruses and a significant safety profile due to the natural
clonal selection.
Although the safety profile of ACAM2000 is well established, a possible concern for the use of this virus in
cancer patients is increased toxicity due to virus amplification within the tumor and cancer-related immunosuppression as commonly observed particularly in advanced
stage patients [22].
In preclinical studies we confirmed that ACAM2000
is a very potent oncolytic virus, able to infect and kill
multiple human cancer cells lines in vitro (Table 1).
However, we and others confirmed that the complement system can neutralize most of the viral particles after intravenous deployment [23]. Therefore, we
suggested that the viral particles taken up by autologous SVF cells would be protected from the patients’
immune system, thus allowing effective delivery to
the tumor sites. In addition, SVF contains stem cells
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Table 1 Oncolysis of a panel of human tumor cell lines
after infection with ACAM2000
Hours
post Infection

Human tumor cell line (percent viability)
PC3

DU145

MDA-MB-231

A549

24

67

100

85

80

48

64

80

63

45

72

33

66

36

41

96

13

51

21

30

exhibiting a natural tropism towards tumor sites, which
could be exploited to transport the viral payloads
directly to the tumor sites [24]. Therefore, we designed
a clinical trial utilizing autologous SVF cells incubated
with vaccinia virus (ACAM2000/SVF) in patients with
advanced solid tumors or AML. The current study is a
first-in-human trial to determine the safety and feasibility of this approach in patients with advanced solid
cancers or AML.

Methods
Therapeutic efficacy of ACAM2000 in vitro

We analyzed the anticancer therapeutic efficacy of
ACAM2000 in vitro against human prostate cancer cell
lines PC3 and DU145, triple negative breast cancer cells
MDA-MB-231 and lung adenocarcinoma line A549.
Tumor cells were seeded on 96-well plates 24 h prior to
infection. The following day, cells were almost confluent and were infected with 50 μl of DMEM media supplemented with 2% fetal bovine serum (FBS) containing
appropriate amount of ACAM2000 (MOI of 1). Control
cells were left untreated. After 1 h of incubation the
media were replaced with DMEM supplemented with
10% FBS. Tumor cell death was then analyzed 24, 48,
72 and 96 h post treatment by MTT assay as follows. At
24, 48, 72, or 96 h after infection of cells, medium was
replaced by 100 uL MTT solution at a concentration
of 2.5 mg/ml MTT dissolved in DMEM and incubated
for 2 h at 37 °C in a 5% C
 O2 atmosphere. After removal
of the MTT solution, the color reaction was stopped
by adding 150 uL 1 N HCl diluted in isopropanol. The
optical density was then measured at a wavelength of
570 nm with a reference wavelength of 650. Uninfected
cells were used as reference and were considered as
100% viable.
Clinical trial

This open-label, non-randomized dose-escalation trial
was approved by the International Cell Surgical Society
Institutional Review Board. Written informed consent

was obtained from all patients prior to treatment, and the
study was conducted in compliance with Good Clinical
Practice guidelines.
Eligibility

Patients (≥ 18 years) were required to have a histologically proven, primary or recurrent, advanced (staging
defined by the American Joint Committee on Cancer
(AJCC; 7th Edition) stage III or IV, and/or aggressive
(defined as published disease-specific survival rates less
than 20% at 5 years following best currently available
therapies) solid organ cancers. Two IRB exemptions were
made to include two patients with AML. All patients had
to be able to understand and be willing to sign a written informed consent. They had to have no continuing
acute toxic effects of any prior therapy, including but
not limited to biological therapy, radiotherapy, chemotherapy, or surgical procedures, i.e., all such effects
must have resolved to Common Terminology Criteria
for Adverse Events (CTCAE, Version 4.0) Grade ≤ 1. Any
other surgery (except biopsies) must have occurred at
least 28 days prior to study enrollment. ECOG performance Status of 0 to 2 was acceptable. A life expectancy
of at least 3 months was required. Also, adequate organ
and marrow function was required, as follows: Absolute
neutrophil count (ANC) ≥ 1.5 × 109; Platelets ≥ 100 ×
109 (without platelet transfusion); Hemoglobin ≥ 9.0 g/
dL (with or without red blood cell (RBC) transfusion);
Serum creatinine ≤ 1.5 × upper limit of normal (ULN);
Bilirubin ≤ 1.5 × ULN; ALT and AST at ≤ 2.5 × ULN
(in case of liver metastasis AST/ALT at ≤ 5.0 × ULN);
LDH ≤ 1.5 × ULN. Women of child-bearing potential
and men with partners of child-bearing potential had to
agree to use adequate contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry,
for the duration of study participation, and for 90 days
following completion of therapy. Women of child-bearing
potential had to have negative pregnancy test prior to initiating study drug dosing. All patients had to be willing
and able to comply with scheduled visits, the treatment
plan, imaging and laboratory tests.
Excluded from the study were all patients with a current or anticipated use of other investigational agents or
marketed anticancer agents. Also excluded were patients
who have received chemotherapy or radiotherapy within
4 weeks prior to entering the study or has not recovered
from adverse events due to agents administered more
than 4 weeks earlier. Other exclusion criteria included
immune system disorders (including acquired immunodeficiency syndrome (AIDS), HIV infection or hepatitis
B or C); Patients who were receiving additional immunosuppressive therapy or any steroids (except concurrent corticosteroid usage if no more than 20 mg per day,
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prednisolone equivalent is applied); Patients who have
received prior gene therapy or therapy with cytolytic
virus of any type; Patients with clinically significant cardiac disease (New York Heart Association Class III or IV)
including pre-existing arrhythmia, uncontrolled angina
pectoris, and myocardial infarction 1 year prior to study
entry, or Grade 2 or higher compromised left ventricular
ejection fraction; Patients with dementia or altered mental status that would prohibit informed consent; patients
with severe or uncontrolled medical disorder that would,
in the investigator’s opinion, impair ability to receive
study treatment (i.e., uncontrolled diabetes, chronic renal
disease, chronic pulmonary disease or active, fever, systemic and/or uncontrolled infections, psychiatric illness/
social situations that would limit compliance with study
requirements); patients receiving concurrent antiviral
agent active against vaccinia virus (e.g., cidofovir, vaccinia
immunoglobulin, imatinib, ST-246) during the course of
study; patients with known allergy to ovalbumin or other
egg products; patients with clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed
skin wounds or ulcers) as assessed by the Principal Investigator during screening and during the study; patients
with a history of allergy to iodinated contrast media;
patients with an active dental infection or recent dental
work within 2 weeks of deployment; patients with known
brain metastases were excluded from this clinical trial
because of their poor prognosis and because they often
develop progressive neurologic dysfunction that would
confound the evaluation of neurologic and other adverse
events.
Treatment

Patients were admitted to the outpatient clinic and a
mini-liposuction procedure was performed to isolate up
to 100 milliliters of adipose tissue. All patients received
local anesthesia consisting of lidocaine 0.5% with epinephrine 1:400,000 with H
 CO3 8.4% titrated to pH of 7.4.
Then sterile prep was performed, followed by liposuction
procedure utilizing the Time-Machine™ device, fat processing unit (syringe) and 2.5–3 mm cannula. Bacitracin ointment and a small bandage were secured over the
wound along with a compressive bandage. The SVF cells
were prepared in a closed system according to an established protocol [25]. Specific amounts of isolated adipose
tissue, numbers of isolated SVF cells and their viability
levels are listed in Table 2.
The ACAM2000 vaccine was prepared according to
manufacturer’s protocol. After reconstitution of the lyophilized preparation, each vial contained approximately
2.5–12.5 × 107 plaque-forming units (pfu) of live vaccinia
virus. Specific amount of ACAM2000 vaccine was added
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Table 2 Isolation of adipose tissue and characterization
of SVF cells
Patient
ID

Volume of adipose
tissue (ml)

1

40

3

50

4

50

5

50

8

30

10

50

14

50

15

100

18

40

21

50

22

51

23

50

24

51

25

50

26

50

27

29

28

90

29

50

30

90

31

10

32

50

33

50

34

50

35

50

36

50

47

50

Total number
of SVF cells

Viability of
SVF cells (%)

34 × 106

76

196 × 106

62

29 × 106

94

19 × 106

78

30 × 106

96

46 × 106

91

147 × 106

88

59 × 106

70

9.4 × 106

46

32 × 106

78

20 × 106

75

66 × 106

60

94 × 106

79

34 × 106

87

67 × 106

95

214 × 106

86

42 × 106

86

216 × 106

92

80 × 106

93

20 × 106

65

14 × 106

82

49 × 106

84

54 × 106

75

32 × 106

77

114 × 106

86

6

46 × 10

47

Patients’ adipose tissue was obtained aseptically in the operating room and
processed in sterile conditions to isolate the SVF cells

to a labeled 20 cc syringe containing the SVF cells to
achieve multiplicity of infection (MOI) = 1. The syringe
was then placed on a rotator inside a 37° incubator, and
was incubated for 15 min to 1 h with constant rotation at
20 rpm.
Twenty-four patients with solid tumors and two
patients with AML received a single treatment with
ACAM2000/SVF. Six patients received systemic intravenous application only, one patient received intratumoral application only, 15 patients received combination
intravenous with intra-tumoral deployment, 3 patients
received intravenous and intra-peritoneal injection and
1 patient received intravenous, intra-tumoral and intraperitoneal injections. To confirm the safety and tolerability of ACAM2000/SVF treatment, a dose escalation
was incorporated into the study design. The dose range
for ACAM2000 in this trial was between 1.4 × 106 and
1.8 × 107 pfu.
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Table 3 Routes of administration and dose of injected SVF
cells loaded with ACAM2000
Patient
ID

Route of administration and dose (SVF cell numbers)

1

2.5 × 106

3
4
5
8
10
14
15
18
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
47

I.V.

I.T.
6

1.4 × 10
6

3 × 10

6

3 × 10

6

1.2 × 107
1.5 × 106
6

3.1 × 10
6

3 × 10

6

3 × 106

3 × 10

6 × 106

6

7 × 106

2.4 × 10
6 × 106

5

4.8 × 10

1.5 × 106

6

3.6 × 10

6

6.6 × 10
6

1 × 10

2.1 × 106
2.1 × 106
6

2.1 × 10
6

5

8.4 × 10

5

7.5 × 10
5

5

6.5 × 10
6

3 × 10

5
6

1.4 × 10

6

6.6 × 10

6

2 × 10

9 × 105

3 × 106

6.6 × 106
1.3 × 107
3 × 106
3 × 106

5

3 × 106

9 × 10

3 × 106

5

1.4 × 106

5.6 × 10

5

1.4 × 106

6.5 × 10
5

5

5.4 × 10

5

2.2 × 10

1.4 × 106
1.4 × 106

5

3 × 106

6

1.4 × 106

7 × 10
5 × 10

3.6 × 106

3 × 106

9 × 105

7 × 10

3 × 106

3 × 106

2 × 10

6

1.8 × 107

3 × 106

6

1 × 10

7 × 10

3 × 106

1.6 × 10

1 × 10

6

7 × 10

2.5 × 106

6

6

2 × 10

3 × 10

Total

6

4.6 × 10

3 × 10

I.P.

c. Intra-peritoneal: the SVF incubated with vaccinia
virus was delivered by intra-peritoneal injection at
the investigator’s clinical site or at Desert Medical
Imaging with ultrasound guidance. The injection volume and number of injected cells varied depending
on tumor type.

1.4 × 106
5 × 106

Patients’ SVF cells were isolated and incubated with ACAM2000 at a ratio of 1:1
(MOI 1) before the I.V., I.T. and I.P. injections

Deployment methods

Specific doses of injected SVF cells loaded with
ACAM2000 at each route of administration are listed in
Table 3.
a. Intravenous: the non-expanded, autologous stromal
vascular fraction (SVF) extracted from up to 100 ml
of lipoaspirate and purified by collagenase digestion
and a series of washing steps and containing up to
100 million cells incubated with vaccinia virus was
delivered by intravenous injection in a volume of
20 mL.
b. Intra-tumoral: the SVF incubated with vaccinia virus
was delivered by intra-tumoral injection at the investigator’s clinical site or at Desert Medical Imaging
with CT guidance or MRI guidance. The injection
volume and number of injected cells varied depending on tumor type and tumor size and location.

Safety assessments

A complete medical history was taken and a physical
examination performed at screening.
Adverse events were monitored throughout the study
until resolution. In addition, all patients responded to a
weekly questionnaire answering specific questions on
their current condition.
Pharmacokinetics of ACAM2000

We analyzed the pharmacokinetics of ACAM2000 by
quantifying the amount of viral DNA present in the
peripheral blood of patients treated with ACAM2000/
SVF by quantitative PCR (qPCR). Specifically, 0.5–5 ml
peripheral blood from the treated patients were collected in Vacutainer K2EDTA blood collection tubes
(Becton, Dickinson, NJ) before treatment, 1 min, 60 min,
1 day, 1 week, 1 month, 3 month and 6 months after
treatment. DNA was extracted using the Quick-gDNA™
Blood MidiPrep (Zymo Research, CA). The copy number amount of the ACAM2000 gene A56R was quantified by qPCR using PowerUp™SYBR® Green Master Mix
(Thermofisher, CA) and the following primers: A56R-F
CAT (CAT CTG GAATTGTCA CTA CTA AA), A56RR (ACG GCC GAC AAT ATA ATT AAT GC) described
previously by Dr. Damon group at Poxvirus and Rabies
Branch, Division of Viral and Rickettsial Diseases
National Center for Zoonotic, Vector-Borne and Enteric
Diseases, Centers for Disease Control and Prevention
(CCID/CDC) [26]. A pUC57 plasmid containing a single copy of A56R open reading frame from ACAM2000
was created (Vectorbuilder—Cyagen Biosciences Inc,
CA, USA) for use as a positive control and to generate a
standard curve for the qPCR assays. Data were recorded
and analyzed using an ABI-PRISM 7700 Sequence Detection System (Applied Biosystems) and Sequence Detector
Software (SDS v2.2).
Flow cytometry and cytokine analysis

Blood samples for PBMC Flow Cytometry and Cytokine
analysis were collected in Vacutainer Heparin blood
collection tubes at Baseline and 1 day, 1 week, 1 month,
3 months and 6 months following the treatment. PBMC
were isolated by Ficoll-Paque method. Plasma samples
for cytokines analysis were isolated by centrifugation of
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blood sample. All PBMC and Plasma samples were sent
for analysis to the Immunologic Monitoring Laboratory
(IML) at the University of Pittsburgh Cancer Institute.
The IML has an independently monitored and extensive quality control (QC) and quality assurance (QA)
program to ensure the validity of test results and safety/
quality of therapeutic products, and participates in
external proficiency panels. The IML also serves as the
Central Immunology Laboratory for the Eastern Cooperative Oncology Group (ECOG). All activities were
carried out in accordance with Good Laboratory Practices as outlined in Title 21 of the U.S. Code of Federal
Regulations Part 58, using Standard Operating Procedures (SOP) and including appropriate quality control.
Efficacy evaluation

Although this Phase I clinical study was designed to
establish the safety and tolerability of ACAM2000/
SVF, we were able to assess some initial efficacy signals following treatment with the ACAM2000/SVF
combination. Brief case reports for two of the responding patients are presented in the results section. Most
patients were not evaluable by response evaluation criteria for solid tumors (RECIST) criteria, because all of
their tumors were not measured over time.
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Table 4 Demographics
Age (years)
Median

60.4

Range

19–92

Gender

N

%

Male

15

58

Female

11

42

Cancer type
Lung cancer

Descriptive statistics for the safety and efficacy assessments were calculated and displayed by group. KaplanMeyer curves displaying the percentage of patients who
survived after a given number of months were calculated for various groups in order to detect whether the
treatment with ACAM2000/SVF had an effect on survival. Patients who dropped out of the study before it
was completed were censored from the calculation of
the survival curves. The set of curves were for patients
with: (a) present skin rashes; (b) persistent viral DNA
in the blood, and (c) for patients who had both persistent viral DNA in the blood and skin rashes (Fig. 3). For
each group of patients, both a Gehan-Breslow-Wlcoxon
and Mantel-Cox t-tests were used to determine any
degree of statistical significance, and the median survival rates were calculated for all groups.

Results
ACAM2000 is effective against multiple human tumor cell
lines in vitro

ACAM2000 virus strain killed all tested human cancer cell lines efficiently, including prostate cancer cell
lines PC-3 and DU154, triple negative breast cancer

%
4

Breast cancer

2

8

Prostate cancer

3

12

AML

2

8

Pancreatic cancer

2

8

Colorectal cancer

2

8

Head and Neck cancer

4

15

Adrenal cancer

1

4

Liver cancer

1

4

Astrocytoma

1

4

Bronchial carcinoid

1

4

Ovarian cancer

1

4

Uterine cancer

1

4

Sarcomatoid

1

4

Squamous cell carcinoma neck

1

4

Esophageal cancer

1

4

Thyroid cancer

1

4

Route of administration

Statistical methods

N
1

Intravenous (IV)
Intravenous + Intratumoral

Intratumoral (IT)

Intraperitoneal (IP) +IV

IV + IT + IP

N
6

%
23

15

58

1

4

3

12

1

4

cells MDA-MB-231 and lung adenocarcinoma line A549
(Table 1).
Patient demographics

As shown in Table 4, twenty-six patients were enrolled
in this study—15 male and 11 female patients. Twentyfour patients with 15 different solid tumor types and 2
patients with AML were enrolled.
Toxicity

As shown in Table 5, self-limiting skin rashes and
small lipo-puncture bleeding were the only treatmentrelated adverse events in this study. These self-limiting
skin rashes are an expected adverse reaction to the
ACAM2000 administration. No other treatment-related
AEs were reported. No infusion-related AEs were
reported. No AEs leading to study discontinuation were
reported. There was no apparent dose-dependent effect
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Table 5 Adverse events
Adverse events

Number

%

Related

Resolved

Skin rashes

8

40

Yes

Yes

Lipo- puncture bleeding

1

5

Yes

Yes

Fever (100.5 F)

2

10

No (10 days and 16 days a/t)

Yes

Pain

4

20

No (7 days, 10 days and 1 month a/t)

Yes

Hemoptysis

1

5

No (2 months a/t)

Yes

Pleural effusion

1

5

No (3 months a/t)

Yes

Headache and weakness of one side

1

5

No (3 weeks a/t)

Yes

Blood Transfusion

1

5

No (10 days a/t)

Yes

Pneumonia

1

5

No (16 days a/t)

Yes

a/t: After treatment; pt: patient

in the type or severity of AEs that occurred following
ACAM2000/SVF treatment. Three patients had presence
of viral DNA in peripheral blood 1 month after treatment
without experiencing any AE.
Another important finding of this study was that 18
patients experienced virus-related and inflammationrelated symptoms at the tumor sites approximately
2 weeks after treatment. Specifically, patients described
this effect as “burning sensation”, fullness, heaviness and
warmness, pointing at their respective tumor/metastatic
sites—a condition lasting 2–4 weeks. These symptoms
were self-limiting and did not require any treatment.
Flow cytometry and cytokine analysis

Flow cytometry results: Flow cytometry data on patientderived PBMCs indicated that treatment resulted in
delayed changes that occurred gradually and over
extended periods of time post treatment and without any
dramatic immediate effects that can be linked to potential serious side effects or toxicities (Table 6).
Cytokine analysis results: Analysis of the concentrations of 30 cytokines in the plasma of treated patients
did not reveal any significant and consistent increase
in cytokine levels post treatment. Particular attention
was given to IL-6 levels, as this cytokine has already
been linked to life threatening toxicities during cytokine
release syndrome (CRS). Higher baseline IL-6 levels were
observed in some patients but these remained under
1000 pg/ml far below the 10,000 pg/ml seen in CRS
patients, and were not further increased following therapy. Il-6 levels did increase over time in some patients
with lower baseline levels of IL-6 but these changes
occurred gradually and similar to the observed gradual
increase in VEGF or HGF levels likely reflecting corresponding increases in tumor burden/progression. Interestingly strong trends towards increased plasma levels
of cytokines and chemokines associated with protective
anti-tumor immunity was also evident including: IL-1b,

IL-12, MIP1a, MIP1b, MCP-1, IL-15, IFNγ, IFNα, IL-1R,
IP-10, MIG, IL-8.
All these responses, however, were delayed and took
approximately 3 months to develop, and therefore cannot be associated with any immediate cytokine release
syndrome features or toxic side effects. Representative analysis of 9 cytokines and the relationship with the
appearance of skin rashes in patients is presented on
Fig. 1.
Pharmacokinetics of ACAM2000

In 10 out of 24 patients, ACAM2000 DNA was present
in peripheral blood 1 week post treatment (Fig. 2). In
8 out of those 10 patients, viral DNA was not detected
on day 1 post treatment. In 1 of those 10 patients, viral
DNA was lower on day 1 than on day 7 post treatment.
These results indicate that viral DNA present 1 week
after treatment might be originating from ACAM2000
active replication, probably at tumor sites. In 3 out of
21 patients, ACAM2000 DNA was present in peripheral
blood 1 month post treatment. In one of those 3 patients,
ACAM2000 DNA was present 3 months post treatment.
No ACAM2000 DNA was detected 6 months post treatment in any patient.
Efficacy assessment

An important observation in this study was that
patients with evidence for oncolytic virus activity,
including persistance of viral DNA in the blood from
1 week to 3 months following treatment, or having skin
rashes, demonstrated trends towards longer survival
(Fig. 3). The patients who presented with both persistent viral DNA in the blood and skin rashes showed
strongest trend towards longer survival (Fig. 3c). For
the 11 patients with persistent viral DNA in the blood,
the median survival was 10 months, compared to only
5 months for the patients without persistent viral
DNA in the blood. However, despite these results, the
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Table 6 Representative analysis of main cell populations in patients
Patient ID

TCD4

TCD8

NK

B

1w

1m

B

1w

1m

B

1w

1m

3

24.8

20.0

27.4

20.1

20.1

27.2

8.9

–

10.4

5

8.0

3.4

5.6

3.9

2.6

2.6

19.9

13.5

23.4

8

–

12.9

14.1

–

8.5

10.2

–

3.1

6.6

10

13.4

13.6

9.6

8.5

18.7

17.5

7.3

–

–

14

30.8

35.7

36.9

32.3

31.0

28.6

5.0

3.7

3.1

15

12.6

9.2

79.9

7.8

8.0

7.3

16.3

12.6

13.9

18

12.9

11.6

13.6

4.1

8.8

5.7

11.1

3.6

10.3

21

13.8

17.9

14.6

3.4

4.1

4.0

17.6

15.9

21.7

24

49.0

32.3

51.0

6.0

3.7

6.1

6.9

3.3

5.7

26

15.0

16.6

14.1

15.9

16.3

13.7

20.9

21.0

16.1

27

22.4

19.1

8.9

9.3

11.5

3.8

4.8

10.3

6.4

28

48.2

36.4

41.9

5.2

6.5

5.6

–

8.6

6.5

29

0.4

0.6

0.6

1.2

2.1

1.7

1.6

2.2

1.7

30

22.6

22.9

23.7

8.6

7.1

14.3

6.3

6.0

6.4

Patient ID

MDSC

Tem

Tcm

B

1w

1m

B

1w

1m

B

1w

1m

3

0.6

0.6

–

1.8

2.1

2.9

1.5

1.6

2.3

5

1.8

2.3

2.3

0.5

0.3

0.5

0.5

0.3

0.3

8

–

2.7

2.1

–

3.6

3.7

–

0.3

0.3

10

1.6

–

2.0

0.5

–

2.3

0.2

–

14

0.5

0.8

0.3

3.8

3.5

3.1

19.8

17.1

14.8

15

1.1

2.0

1.2

2.1

2.7

2.3

0.5

0.6

0.8

18

2.0

1.9

3.5

0.9

3.2

1.8

0.0

0.1

0.0

21

1.7

2.4

1.7

1.2

1.3

1.4

0.0

0.1

0.1

24

0.3

0.9

0.9

0.5

0.4

0.4

1.2

0.7

1.1

26

0.5

0.7

1.1

2.3

2.6

2.2

0.1

0.2

0.2

27

1.2

0.6

0.4

3.4

3.3

1.2

0.1

0.1

0.1

28

0.5

0.7

0.4

3.3

4.2

4.3

0.2

0.2

0.2

29

9.0

5.1

6.0

0.1

0.2

0.2

0.1

0.2

0.1

30

0.3

0.2

0.2

3.0

2.0

4.3

0.5

0.5

0.5

0.4

Patients’ blood samples were analyzed by flow cytometry at different time-points after treatment: B: baseline; 1 w: 1 week post treatment; 1 m: 1 month post
treatment. Data represent percent of total PBMC. Cell populations: TCD4 (CD3+ CD4 +), TCD8 (CD3+ CD8 +), NK (CD3−CD56 +), MDSC (Lin-DR-CD3 + CD116+), Tem
(CD3+ CD8+ CD45RA-CD197−), Tcm (CD3+ CD8+ CD45RA−CD197+)

survival curves were not statistically significantly different from one another. This is due to the limited
number of patients and/or differences in disease type/
progression that preclude proper and conclusive evaluation of therapeutic benefits at this stage. A median
survival period of 5 months was also calculated for the
sub-cohort of 17 patients in whom no skin rashes were
detected (Fig. 3a), although it should be emphasized
again that no statistically significant differences were
noted amongst the survival curves.
The main purpose of this Phase I clinical study was
to establish the safety and tolerability of ACAM2000/
SVF, as this approach is being tested for the first time in

patients with advanced solid tumors and AML. However,
we were able to assess some initial efficacy signals in several patients.
Patient #21 was 70 years old male diagnosed with
metastatic poorly differentiated squamous cell carcinoma (Stage: IVB). Patient presented with a very large
tumor near right ear heading toward collar bone and
other smaller tumors on the opposite side. Patient previously received XRT to right lesion as well as Paclitaxel
and 5FU. Treatment with ACAM2000/SVF was divided
in 4 independent inoculations performed the same day:
an IV infusion of ACAM2000/SVF and 3 IT injections
into three regions of his right neck tumor. Three weeks
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Fig. 1 Representative analysis of 9 cytokines and the relationship with the appearance of skin rashes in patients. Patients’ plasma samples were
analyzed using The Cytokine Human Magnetic 30-Plex Panel for the Luminex™ platform (Thermo Fisher) at different time-points after treatment:
1 W: 1 week post treatment; 1 M: 1 month post treatment. Data is presented as Log2 of fold change after treatment

post treatment the patient reported itchiness, warmth
and slight enlargement of treated lesion as well as some
oozing (Fig. 4). Biopsy of this lesion at 4 weeks post treatment showed poorly differentiated squamous cell carcinoma arranged in sheets and groups with comedo-type
necrosis, inflammation and surrounding fibrovascular
stroma. Six weeks post treatment patient began treatment with Opdivo (Nivolumab, anti-PD-1) q2w 3 mg/
kg. Three months post ACAM2000/SVF treatment
this patient received XRT (13 doses) accompanied with
fatigue, nausea, and difficulty swallowing. Approximately
2 weeks after completion of XRT treatment the tumor
began shrinking, leading to a substantial size reduction at
6 months post ACAM2000/SVF treatment, weight gain
and significant improvement of overall condition (Fig. 4).
Patient #47 was 67 years old male diagnosed with metastatic papillary thyroid carcinoma with cervical lymphadenopathy. Left thyroidectomy and isthmectomy was
done in 1985. Patient presented with a large clearly visible right supraclavicular lymph node, a smaller left cervical node and several smaller palpable cervical nodes.
Treatment with ACAM2000/SVF was divided in 6 independent intra-tumoral inoculations performed the same
day: 4 IT injections into four regions of the larger right
supraclavicular lymph node and 2 IT injections into two
regions of the smaller cervical lymph node. Ipilimumab

(anti-CTLA-4) was injected 36 h post ACAM2000/SVF
injections as a single IT injection of 25 mg Ipilimumab
into the right node only. Approximately 4 weeks post
treatment the patient reported enlarged, warmer and
reddish right node and no inflammatory symptoms in
the left node (Fig. 5). Two months post treatment the
right tumor was much smaller, softer and much less
inflamed, while no changes in consistence or appearance were noted in the left treated node. Three months
post treatment the patient experienced almost complete
eradication of the right tumor with a very small hard area
notable only on palpation (Fig. 5).

Discussion
This Phase I clinical study was designed to establish the
safety and tolerability of ACAM2000/SVF and assess
initial efficacy signals in relationship to ACAM2000/
SVF treatment. The most important finding of this study
was that ACAM2000/SVF can safely be administered
in patients with advanced metastatic solid tumors or
advanced AML. Two important aspects of this finding
will have clear clinical implications in future trials: (i)
this is the first clinical study confirming the safety of a
TK-positive oncolytic vaccinia virus delivered by autologous cells, and (ii) safety administration of ACAM2000/
SVF is confirmed in severely immunocompromised
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Fig. 2 Viral DNA in patients’ peripheral blood. DNA was extracted using the Quick-gDNA™ Blood MidiPrep (Zymo Research, CA). The copy number
amount of the ACAM2000 gene A56R was quantified by qPCR using PowerUp™ SYBR® Green Master Mix (Thermofisher, CA). Viral DNA was analyzed
by qPCR before treatment (bt), and 1 min (1 min), 60 min (60 min), 1 day (1d), 1 week (1 w), 1 month (1 mo), 3 months (3 mo) and 6 months (6 mo)
after treatment

patients with advanced cancer. This trial also validates
the safety of combining ACAM2000 and SVF as a delivery vehicle that protects the virus from complement
inactivation in the blood. No significant treatment-associated toxicities were observed in any of the 26 patients
who received IV, IP and IT injections of ACAM2000
loaded onto freshly isolated SVF, showing that ex vivo

infection of the SVF can be done in a manner that is safe
to the patients.
Our pharmacokinetics data indicate that the injected
virus (viral DNA detected by qPCR) is rapidly cleared
from blood circulation within an hour. In some patients
the viral DNA reappeared 1 week to 1 month following
treatment, and importantly often in the absence of any
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Fig. 3 Kaplan-Meier plots showing the relative survival of a total of
25 patients (23 patients with solid tumors and 2 patients with AML).
a Patient survival relative to the presence of persistent vaccinia virus
DNA in the blood for 1 week to 3 months post treatment. Median
survival: without persistent VV, 5 months, (n = 14) vs. with persistent
VV, 10 months (n = 11). b Patient survival relative to reported
presence of skin rashes. Median survival: without skin rashes,
5 months (n = 17) vs. with skin rashes, undefined (n = 8). c Patient
survival relative to the presence of both skin rashes and persistent
vaccinia virus DNA in the blood. Median survival: with either or none,
5 months, (n = 20) vs. with both, undefined (n = 5). Vertical tick marks
indicate patients who dropped from the study or were censored from
analysis after switching to alternative cancer treatments

skin rashes which suggests intra-tumoral virus infection
and amplification. Despite the potential for sustained
intra-tumoral virus amplification, none of the treated
patients developed uncontrolled viremia or manifested
widely spread skin rashes or any other evidence for systemic toxicity, supporting our conclusion that intratumoral virus amplification does not pose a significant
safety concern.
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AEs associated with smallpox vaccination in general
are fever, headache, myalgia, rigors, sweating, fatigue,
asthenia, nausea, vomiting, general reddening of the
skin, lymph node swelling, and immunological parameter changes (e.g., cytokines). In the past, various vaccinia
virus strains (DryVax, Lister) have been applied clinically to cancer patients [13, 14, 27, 28]. Positive treatment
results have been reported, along with some severe local
reactions (rash, erythema) as well as systemic side effects
(headache, malaise, fever, flu-like symptoms), but no lifethreatening toxicities. These previously published results
provided the rationale and scientific justification for us
to conduct further clinical investigation of the oncolytic
potential of ACAM2000, the current plaque-purified and
naturally attenuated smallpox vaccine. The most concerning toxicities observed with the use of ACAM2000
as a smallpox vaccine are rare cardiac complications
(arrhythmias, pericarditis, myocarditis, and dilated cardiomyopathy). No cardiac complications or systemic side
effects were observed in any patient participating in the
current trial. This finding contrasts with previous clinical
trials with “naked” vaccinia viruses, where most patients
experienced fever, chills and other flu-like symptoms for
the first 6–24 h following treatment [13, 14].
We have demonstrated that ACAM2000 is oncolytic
and efficiently infects and kills human cancer cell lines,
while the extensive use of the same virus as a smallpox
vaccine has conclusively demonstrated self-limiting
amplification at the site of administration in the skin
with virtually absent local or distant spread to other tissues and organs in the body [15]. These observations
likely reflect the combination of efficient neutralization
in circulation and the inability of the virus to infect and
amplify in healthy cells, apart from the limited amplification seen in skin keratinocytes. This study confirmed
the previous observations with various heterogeneous
and more virulent smallpox vaccines previously licensed
in the USA and Europe that the AEs associated with
the application of smallpox vaccines to cancer patients
are minor and rarely require medical attention [27, 28].
Overall, the observed treatment-related adverse events
in the study were rare. These findings suggest that
ACAM2000 is well tolerated and can be safely administered to patients with cancer.
Despite this positive safety data, the investigator administering ACAM2000 must be prepared for
extremely rare but possible severe local and systemic
reactions, historically associated with patients who had
inherent or treatment-related immunodeficiency. In
the unlikely scenario that such complications do occur,
the adverse events and complications can be effectively
controlled by the available antidote vaccinia immune
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Fig. 4 Patient #21: tumor regression of patient’s poorly differentiated squamous cell carcinoma (Stage: IV_B)

globulin (VIG) [29]. Although cardiac toxicities were
not reported by any patient in our safety study, specific efforts should be taken to closely monitor the cardiac condition of all patients undergoing ACAM2000
treatment in an effort to detect such symptomatic or
asymptomatic virus-related complications and prevent
possible cardiac events by timely administration of the
antidote, if considered necessary by the monitoring
physician.
The therapeutic potential of any oncolytic virus
depends on the fine balance between the induction of
antiviral immunity, leading to clearance of the oncolytic

virus, and the development of antitumor immunity, leading to tumor cell eradication and eventually to potent and
durable clinical responses. The current trial represents an
attempt to fine tune this balance by protecting the oncolytic virus using autologous SVF cells to avoid premature
clearance of the virus, allowing sufficient time for viruses
to replicate and kill tumor cells and to initiate antitumor
immunity. Interestingly, the analysis of this safety trial
suggests that there is no positive correlation between
augmented vaccinia virus activity and increased tumor
burden, tumor-associated immunosuppression, and
shorter survival. Overall, the trends towards improved
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Fig. 5 Patient #47: tumor regression of patient’s metastatic papillary thyroid carcinoma. Treatment effects in the treated right supraclavicular lymph
node are shown

survival associated with vaccinia virus activity in vivo
including the persistence of viral DNA in the blood, visible skin rashes, and/or both (Fig. 3), are intriguing and
may indeed have therapeutic significance.
The two case reports presented here emphasize the
importance of combining checkpoint inhibitors and
oncolytic viruses to achieve better clinical responses.
The synergistic effects of this combination have been
described previously by us [30] and other groups [31, 32].
Therefore, these current trial findings will be utilized in
future clinical trial designs with this synergistic approach.

When evaluating the efficacy outcomes of the current
study, it is important to note that the primary
objective of this study was to evaluate the safety of
the combination of ACAM2000 and SVF in patients
with advanced tumors. Therefore, we acknowledge
that the interpretation of the efficacy outcomes is limited by the small size of the study population (n = 26).
Only a randomized trial would be able to definitively
demonstrate the efficacy of the ACAM2000/SVF
combination.
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Conclusions
The aggregate safety, tolerability, and PK results indicated
that ACAM2000/SVF was well tolerated in this study
with 26 patients with advanced cancers (Stage III or IV).
The MTD was not reached.
In summary, our study show that: (i) the combined
application of SVF and ACAM2000 was very safe in all
patients; (ii) the results of the plasma cytokine assays
suggested mild inflammatory reaction starting approximately 1 week after treatment, not associated with any
clinical symptoms; (iii) most patients experienced virusrelated and inflammation-related symptoms at the tumor
sites approximately 2 weeks after treatment; (iv) the flow
cytometry assays show induction of immune response
with memory T cells approximately 1 month after treatment; (v) there is a trend towards improved survival associated with vaccinia virus activity in vivo including the
persistence of viral DNA in the blood, visible skin rashes,
and/or both; (vi) some patients experienced significant
tumor size reduction, especially when the ACAM2000/
SVF treatment was combined with checkpoint inhibition.
These early promising results must be re-evaluated
within a larger and more homogeneous cohort of patients
to confirm the feasibility and effectiveness of this novel
treatment approach.
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